CURRICULUM VITAE. Rocco Giovanni Piazza PERSONAL DATA:

Size: px

Start display at page:

Download "CURRICULUM VITAE. Rocco Giovanni Piazza PERSONAL DATA:"

Darleen Rose
9 years ago
Views:

1 CURRICULUM VITAE Rocco Giovanni Piazza PERSONAL DATA: Date and place of birth: 26 th July 1974, Reggio Calabria (Italy). Citizenship: Italian Address: Via Carducci 8, Lissone (MB) - Italy Phone [email protected] EDUCATION: - In 1998: M.D., University of Pavia (110/110 cum laude). - In 1999: admission at the Italian Ph.D. School for Advanced Studies (SAFI). - In 2002: PhD (Biochemistry) at the Department of Biochemistry, University of Pavia. - In 2006: Post graduate education in Haematology at the S. Gerardo Hospital of Monza. - Starting from 2009, researcher (MED/15 - Haematology) at the University of Milano- Bicocca - Known languages: Italian, English, and French (scholastic level). WORK EXPERIENCE: : PhD in Biochemistry, Department of Biochemistry, University of Pavia : PostDoc in Molecular Biology, Division of Experimental Oncology, Oncogenic Fusion Proteins Unit, Istituto Nazionale Tumori, Milano Italy Clinical Haematology Fellow, Department of Haematology, San Gerardo Hospital, Monza Italy PostDoc - Oncohaematology, Department of Clinical Medicine, University of Milano-Bicocca, Milano Italy Researcher in Haematology, Department of Clinical Medicine, University of Milano-Bicocca, Milano Italy.

- In 1999: admission at the Italian Ph.D. School for Advanced Studies (SAFI). - In 2002: PhD (Biochemistry) at the Department of Biochemistry, University of Pavia.

2 PRESENT RESEARCH AREA: - High-throughput second-generation sequencing of cancer genomes. - Molecular mechanisms of drug resistance. - Genetic and epigenetic regulation of gene expression in normal and neoplastic cells. - Functional inhibition of oncogenic fusion proteins with tyrosine kinase activity using tyrosine-kinase inhibitors.

- Genetic and epigenetic regulation of gene expression in normal and neoplastic

3 AWARDS AND HONORS: , Italian Chemistry Games: first place at regional level, third place at national level : School of Medicine (University of Pavia): ranked first at the admission test (9.75/10) : M.D.: 110/110 cum laude : SAFI prize with the thesis: Immunology and mathematics : SAFI prize with the thesis: Virtual ants and swarm intelligence : SAFI prize with the thesis: Neural networks and DNA microchips : PhD in Biochemistry, Department of Biochemistry, University of Pavia : Post graduate education in Haematology: 70/70 cum laude : American Association for Cancer Research - Pezcoller Foundation Scholar-in- Training Award for the AACR Annual Meeting 2008 with the abstract: Reversal of glucocorticoid resistance in human lymphoid malignancies with histone deacetylase inhibitors. CLINICAL TRIALS: - Investigator in Clinical Trial 3160A4-200-WW (NCT ): Open-label, continuous daily dosing, two-part safety and efficacy study of SKI-606 (bosutinib) in Philadelphia chromosome positive leukemias (Ph+). - Investigator in Clinical Trial 3160A WW (NCT ): Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML. - Investigator in Clinical Trial A (NCT ): An Investigational Drug, Crizotinib (PF ), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK). - Investigator in Clinical Trial AP24534 (NCT ): PONATINIB for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL). - Investigator in Clinical Trial CA (NCT ): An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL ) vs. Standard Dose Imatinib (400

- 2000: SAFI prize with the thesis: Virtual ants and swarm intelligence. - 2001: SAFI prize with the thesis: Neural networks and DNA microchips.

4 mg) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia. - Investigator in Clinical Trial CA (NCT ): A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec). - Investigator in Clinical Trial CINC424A2352 (NCT ): A Randomized Study of INC424 (INCB018424) Tablets Compared to Best Available Therapy in Subjects With Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis. - Investigator in Clinical Trial EWALL-PH-01: Dasatinib (Sprycel ) and Low Intensity Chemotherapy for First-Line Treatment In Elderly Patients with De Novo Philadelphia Positive ALL. - Investigator in Clinical Trial ISAV STUDY - Imatinib Suspension and Validation. - Investigator in Clinical Trial ILTE - Imatinib Long Term side-effects study. - Investigator in Clinical Trial (NCT ) Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY). - Investigator in Clinical Trial The quality of life in chronic myeloid leukemia patients treated with Imatinib (QUALIMA).

100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec).

5 SELECTED PUBLICATIONS: - Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, Antolini L, Mologni L, Donadoni C, Papaemmanuil E, Schnittger S, Kim DW, Boultwood J, Rossi F, Gaipa G, De Martini GP, Francia di Celle P, Jang HG, Fantin V, Bignell GR, Magistroni V, Haferlach T, Pogliani EM, Campbell PJ, Chase AJ, Tapper WJ, Cross NCP, Gambacorti-Passerini C. Nat Genet Dec 16;45(1): Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C. Am J Hematol Sep 26. doi: /ajh Piazza R, Pirola A, Spinelli R, Valletta S, Redaelli S, Magistroni V, Gambacorti-Passerini C. Nucleic Acids Res Sep 1;40(16):e123. Epub 2012 May 8. - Gambacorti-Passerini C, Piazza R. Am J Hematol Jul;86(7): doi: /ajh Magistroni V, Mologni L, Sanselicio S, Reid JF, Redaelli S, Piazza R, Viltadi M, Bovo G, Strada G, Grasso M, Gariboldi M, Gambacorti-Passerini C. PLoS One. 2011;6(11):e Bachmann PS*, Piazza RG*, Janes ME, Wong NC, Davies C, Mogavero A, Bhadri VA, Szymanska B, Geninson G, Magistroni V, Cazzaniga G, Biondi A, Miranda-Saavedra D, Göttgens B, Saffery R, Craig JM, Marshall GM, Gambacorti-Passerini C, Pimanda JE, Lock RB, (*Joint First Authors), Blood Oct 21;116(16): Marega M*, Piazza RG*, Pirola A, Redaelli S, Mogavero A, Iacobucci I, Meneghetti I, Parma M, Pogliani EM, Gambacorti-Passerini C, (*Joint First Authors), Leukemia Aug;24(8): Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, Gambacorti- Passerini C, Boschelli F, J Clin Oncol Jan 20;27(3): Mologni L, Cleris L, Magistroni V, Piazza R, Boschelli F, Formelli F, Gambacorti- Passerini C, Int J Cancer Apr 15;124(8): Galietta A, Gunby RH, Redaelli S, Stano P, Carniti C, Bachi A, Tucker PW, Tartari CJ, Huang CJ, Colombo E, Pulford K, Puttini M, Piazza RG, Ruchatz H, Villa A, Donella- Deana A, Marin O, Perrotti D, Gambacorti-Passerini C, Blood Oct 1;110(7):

2012 Dec 16;45(1):18-24. - Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C. Am J Hematol. 2012 Sep 26. doi: 10.1002/ajh.23338.

6 - Gambacorti-Passerini C, Tornaghi L, Franceschino A, Piazza RG, Corneo G, Pogliani E, Nat Med Jan;13(1): Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza RG, Magistroni V, Andreoni F, Scapozza L, Formelli F, Gambacorti- Passerini C, Cancer Res Dec 1;66(23): Forlino A, Gualeni B, Pecora F, Torre SD, Piazza RG, Tiveron C, Tatangelo L, Superti- Furga A, Cetta G, Rossi A, Novartis Found Symp. 2006;273: Piazza RG, Magistroni V, Franceschino A, Andreoni F, Tornaghi L, Colnaghi F, Corneo G, Pogliani EM, Gambacorti-Passerini C, Blood Cells Mol Dis Sep-Oct;37(2): Franceschino A, Tornaghi L, Piazza R, Pogliani EM, Gambacorti-Passerini C, Haematologica Jun;91(6 Suppl):ECR14. - Piazza RG, Magistroni V, Andreoni F, Franceschino A, Tornaghi L, Varella-Garcia M, Bungaro S, Colnaghi F, Corneo G, Pogliani EM, Gambacorti-Passerini C, Leukemia 2005 Nov;19(11): Forlino A*, Piazza RG*, Tiveron C, Della Torre S, Tatangelo L, Bonafe L, Gualeni B, Romano A, Pecora F, Superti-Furga A, Cetta G, Rossi A, (*Joint First Authors), Hum Mol Genet Mar 15;14(6): Piazza RG, Magistroni V, Gasser M, Andreoni F, Galietta A, Scapozza L, Gambacorti- Passerini C, Leukemia Jan;19(1): Gambacorti-Passerini C, Piazza RG, Tornaghi L, Pilotti S, Pogliani E, Journal of the National Cancer Institute, Vol. 96, No. 22, November 17, Gambacorti-Passerini C, Piazza RG, D'Incalci M, Blood Sep 1;102(5): Gambacorti-Passerini C, Gunby R, Piazza RG, Galietta A, Rostagno R, Scapozza L, Lancet Oncology, 2003 Feb;4(2): Rossi A, Cetta G, Piazza RG, Bonaventure J, Steinmann B, Superti-Furga A, Pediatric Pathology and Molecular Medicine, 2003 Jul-Aug;22(4): Legeai-Mallet L, Rossi A, Benoist-Lasselin C, Piazza RG, Mallet JF, Delezoide AL, Munnich A, Bonaventure J, Zylberberg L, Journal of bone and mineral research, 2000 Aug;15(8):

2006 Dec 1;66(23):11314-22. - Forlino A, Gualeni B, Pecora F, Torre SD, Piazza RG, Tiveron C, Tatangelo L, Superti- Furga A, Cetta G, Rossi A, Novartis Found Symp. 2006;273:193-206.

treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can

treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods